Maintenance therapy in NSCLC: why? To whom? Which agent?

J Exp Clin Cancer Res · 2011 · PMC3113744 · PMID 21548925

Europe PMC DOI

hedged sentence

0.0853

closest p · 1.7× alpha

0.0853

boldest claim

The sentences

did not reach statistical significancep = .0853so close (0.05 < p ≤ 0.1)

There was a statistically significant advantage in PFS (5.7 versus 2.7 months, p = .0001) with maintenance docetaxel but, despite a 3-months improvement in median OS (primary endpoint), the difference did not reach statistical significance (12.3 vs. 9.7 months, p = .0853)[ 26 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.